Collegium Pharmaceutical Inc. (COLL)
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?
The consensus price target hints at an 111.4% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript
Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.68 per share a year ago.
Collegium Pharmaceutical Q2 Earnings Call Highlights
Collegium Pharmaceutical NASDAQ: COLL reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower revenue from the NUCYNTA pain franchise.
Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating
Collegium Pharmaceutical (COLL) is transitioning from a pain-management roll-up to a CNS platform, leveraging stable pain cash flows to fuel ADHD franchise growth. The AZSTARYS acquisition, funded with $350M cash and $300M debt, is expected to deliver $60–70M revenue in 2026 and $50M+ annual synergies within 12 months. COLL's 2026 guidance is $865–895M in revenue and $475–500M adjusted EBITDA, with a 55% margin, reflecting only partial-year AZSTARYS contribution and early synergies.
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
COLL gains momentum as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and revenue outlook.
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
